Literature DB >> 28314870

Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals.

Aline C Gomes1, Angélica L Mello1, Manuel G Ribeiro1, Diogo G Garcia2, Clovis O Da Fonseca3, Marcela D'Alincourt Salazar4, Axel H Schönthal5, Thereza Quirico-Santos6.   

Abstract

Monoterpenes such as limonene and perillyl alcohol (POH) are promising natural compounds with pro-oxidant properties partly due to endoplasmic reticulum (ER) stress-induced cytotoxicity, and antioxidant activity owing to their activity as free radical scavengers, inhibition of coenzyme Q synthesis, activation of antioxidant-responsive elements (inducing detoxification enzymes) and induction of apoptosis. Activation of ER-stress responses generates reactive oxygen species (ROS), which are highly reactive free radicals mainly produced during mitochondrial electron transfer for adenosine triphosphate (ATP) synthesis. When cells are subjected to oxidative stress conditions, there is an accumulation of ROS that can lead to irreversible cell injury caused primarily by lipid peroxidation, protein aggregation and/or DNA damage. Malignant tumors, such as glioblastoma multiforme, display elevated rates of oxygen consumption, necrosis and abnormal structural microvasculature. Alterations in the tumor microenvironment are tightly linked to tumor progression and occur as a result of activation of complex signaling networks involving inter-clonal cooperation, cell-matrix interactions and an ongoing inflammatory response leading to genetic and epigenetic alterations. This review will focus on the pro- and anti-oxidant activities of POH, which are greatly dependent on the respective ROS levels within the tumor microenvironment and involve the ER stress response system. As well, some critical aspects of tumor-associated metabolic changes and the consequences of endogenous ROS production for tumor progression will be discussed.

Entities:  

Keywords:  Hypoxia; Perillyl alcohol; Reactive oxygen species; Tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28314870     DOI: 10.1007/s00005-017-0459-5

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  5 in total

1.  Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy.

Authors:  Giselle Faria; Emanuelle Silva; Clovis Da Fonseca; Thereza Quirico-Santos
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

2.  Perillyl alcohol has antibacterial effects and reduces ROS production in macrophages.

Authors:  Rebeca Dantas Alves Figueiredo; Adriana Cabrera Ortega; Laura Andrea González Maldonado; Ricardo Dias de Castro; Mario Julio Ávila-Campos; Carlos Rossa; Sabrina Garcia de Aquino
Journal:  J Appl Oral Sci       Date:  2020-04-27       Impact factor: 2.698

3.  Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.

Authors:  Juliana Guimaraes Santos; Gisele Faria; Wanise Da Cruz Souza Da Cruz; Cristina Asvolinsque Fontes; Axel H Schönthal; Thereza Quirico-Santos; Clovis O da Fonseca
Journal:  Surg Neurol Int       Date:  2020-11-11

4.  Photophysical Properties of Fluorescent Self-Assembled Peptide Nanostructures for Singlet Oxygen Generation.

Authors:  Geovany Albino de Souza; Fabio de Castro Bezerra; Tatiana Duque Martins
Journal:  ACS Omega       Date:  2020-04-08

5.  Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.

Authors:  Giselle M Faria; Igor D P Soares; Marcela D'Alincourt Salazar; Marcia R Amorim; Bruno L Pessoa; Clovis O da Fonseca; Thereza Quirico-Santos
Journal:  BMC Cancer       Date:  2020-04-07       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.